NOVOCURE ($NVCR) posted quarterly earnings results for Q2 2026 on Thursday, July 23rd. The company reported earnings of -$0.13 per share, beating estimates of -$0.34 by $0.21. The company also reported revenue of $183,580,000, beating estimates of $176,171,482 by $7,408,518.
You can see Quiver Quantitative's $NVCR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NOVOCURE Insider Trading Activity
NOVOCURE insiders have traded $NVCR stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $NVCR stock by insiders over the last 6 months:
- FRANK X LEONARD (Chief Executive Officer) has made 0 purchases and 2 sales selling 39,880 shares for an estimated $689,238.
- MUKUND PARAVASTHU (Chief Operating Officer) has made 0 purchases and 2 sales selling 48,623 shares for an estimated $667,213.
- URI WEINBERG (Chf Medical and Innovation Ofr) has made 0 purchases and 3 sales selling 17,145 shares for an estimated $232,177.
- CHRISTOPH BRACKMANN (Chief Financial Officer) sold 6,412 shares for an estimated $85,314
- JERYL L HILLEMAN sold 2,945 shares for an estimated $46,444
- GABRIEL LEUNG sold 2,945 shares for an estimated $46,444
- DAVID HUNG sold 2,945 shares for an estimated $46,444
- W ANTHONY VERNON sold 2,945 shares for an estimated $46,444
- TIMOTHY J SCANNELL sold 2,945 shares for an estimated $46,444
- ALLYSON J OCEAN sold 2,945 shares for an estimated $46,444
- KRISTIN STAFFORD sold 2,945 shares for an estimated $46,444
- MICHAL NATH PURI (Chief Human Resources Officer) sold 1,100 shares for an estimated $14,635
- NICOLAS LEUPIN (Former Chief Medical Officer) sold 1,100 shares for an estimated $14,635
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
NOVOCURE Hedge Fund Activity
We have seen 88 institutional investors add shares of NOVOCURE stock to their portfolio, and 119 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. added 1,961,726 shares (+23.0%) to their portfolio in Q1 2026, for an estimated $21,382,813
- SG AMERICAS SECURITIES, LLC added 966,735 shares (+346.7%) to their portfolio in Q1 2026, for an estimated $10,537,411
- AMERICAN CENTURY COMPANIES INC removed 842,794 shares (-80.9%) from their portfolio in Q1 2026, for an estimated $9,186,454
- CITADEL ADVISORS LLC removed 589,695 shares (-87.3%) from their portfolio in Q1 2026, for an estimated $6,427,675
- MILLENNIUM MANAGEMENT LLC removed 555,451 shares (-85.9%) from their portfolio in Q1 2026, for an estimated $6,054,415
- MORGAN STANLEY removed 528,369 shares (-10.4%) from their portfolio in Q1 2026, for an estimated $5,759,222
- QUANTINNO CAPITAL MANAGEMENT LP added 477,128 shares (+23.7%) to their portfolio in Q1 2026, for an estimated $5,200,695
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
NOVOCURE Government Contracts
We have seen $12,101,375 of award payments to $NVCR over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- OPTUNE PLUS TRANSDUCERS: $99,497
- EXPRESS REPORT: OPTUNE PLUS TRANSDUCERS: $99,497
- OPTUNE TRANSDUCER (6 MONTH RENTAL): $99,497
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
NOVOCURE Analyst Ratings
Wall Street analysts have issued reports on $NVCR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/12/2026
To track analyst ratings and price targets for NOVOCURE, check out Quiver Quantitative's $NVCR forecast page.
NOVOCURE Price Targets
Multiple analysts have issued price targets for $NVCR recently. We have seen 4 analysts offer price targets for $NVCR in the last 6 months, with a median target of $19.0.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $46.0 on 06/18/2026
- Larry Biegelsen from Wells Fargo set a target price of $17.0 on 05/04/2026
- Vijay Kumar from Evercore ISI Group set a target price of $20.0 on 05/01/2026
- David Nierengarten from Wedbush set a target price of $18.0 on 04/16/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
